Holen Sie sich die Stockscreener-App
0.4173
4.55%
-0.0199
Handel nachbörslich:
.42
0.0027
+0.65%
Schlusskurs vom Vortag:
$0.4372
Offen:
$0.409
24-Stunden-Volumen:
1.14M
Relative Volume:
0.69
Marktkapitalisierung:
$95.29M
Einnahmen:
$8.95M
Nettoeinkommen (Verlust:
$-21.49M
KGV:
-3.4775
EPS:
-0.12
Netto-Cashflow:
$-29.24M
1W Leistung:
-15.97%
1M Leistung:
-18.19%
6M Leistung:
-53.58%
1J Leistung:
-69.32%
1-Tages-Spanne:
$0.409
$0.4213
1-Wochen-Bereich:
$0.4011
$0.499
52-Wochen-Spanne:
$0.4011
$1.56
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Firmenname
Lineage Cell Therapeutics Inc
Sektor
Branche
Telefon
510-871-4188
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Vergleichen Sie LCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
0.4173 | 95.29M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Eingeleitet | Craig Hallum | Buy |
| 2022-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-08-19 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-03-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
LCTX Stock: A Comprehensive Analysis and Forecast - investchronicle.com
LCTX stock touches 52-week low at $0.48 amid market challenges - Investing.com
Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531 - MarketScreener
Cell Therapy Manufacturing Market Demand, Growth and Future - openPR.com
LCTX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa
B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings - Defense World
B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress - TipRanks
B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating - Marketscreener.com
HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings - Defense World
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World
Cell Therapy Manufacturing Market Poised for Expansion Biotech - openPR
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, - openPR
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright - Defense World
Lineage Cell Therapeutics stock target cut to $3 by Craig-Hallum - Investing.com Australia
Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies - TipRanks
Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock - Benzinga
Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - BioSpace
Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise - Investing.com India
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data By Investing.com - Investing.com South Africa
Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data - Investing.com
Lineage Cell Reports Q4 Revenue Growth, FDA Breakthrough Status for Eye Treatment - StockTitan
Lineage Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 - BioSpace
Atria Wealth Solutions Inc. Makes New Investment in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics (LCTX) to Release Quarterly Earnings on Thursday - MarketBeat
Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday - Defense World
Short Interest in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Decreases By 21.4% - MarketBeat
SG Americas Securities LLC Acquires 18,053 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Cut to $2.00 by Analysts at D. Boral Capital - MarketBeat
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Lowered to $2.00 at D. Boral Capital - Defense World
Lineage begins study of OPC1 delivering device for spinal cord injury treatment - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury -February 11, 2025 at 10:21 am EST - Marketscreener.com
Lineage Initiates Clinical Study Of OPC1 For Spinal Cord Injury -February 11, 2025 at 08:46 am EST - Marketscreener.com
Market Recap Check: Lineage Cell Therapeutics Inc (LCTX)’s Negative Finish at 0.66, Up/Down -2.12 - The Dwinnex
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury - Business Wire
Refrigerated Warehousing Market Revenues to Grow from $85 Billion in 2024 to $241 Billion by 2030 - GlobeNewswire Inc.
Lineage's Next-Gen Spinal Treatment Targets Both Recent & Long-Term InjuriesMajor Trial Expansion - Stock Titan
Lineage Cell Therapeutics Inc [LCTX] Shares Fall Approximately -33.17% Over the Year - Knox Daily
Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):